SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update

SAB Biotherapeutics, Inc. (NASDAQ:SABS) saw a significant decline in short interest in the month of September. As of September 15th, there was short interest totalling 30,200 shares, a decline of 12.7% from the August 31st total of 34,600 shares. Approximately 0.4% of the company’s shares are short sold. Based on an average daily volume of 15,700 shares, the days-to-cover ratio is currently 1.9 days.

SAB Biotherapeutics Stock Down 3.7 %

Shares of SABS opened at $2.57 on Monday. The company’s 50 day simple moving average is $2.73 and its 200-day simple moving average is $3.36. SAB Biotherapeutics has a 12-month low of $2.16 and a 12-month high of $10.50. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.24 and a current ratio of 5.24.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.79) EPS for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.34. SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.04%. The company had revenue of $0.26 million for the quarter. Sell-side analysts expect that SAB Biotherapeutics will post -3.59 earnings per share for the current year.

Institutional Investors Weigh In On SAB Biotherapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. First PREMIER Bank acquired a new stake in shares of SAB Biotherapeutics during the 2nd quarter valued at approximately $60,000. Commodore Capital LP acquired a new position in shares of SAB Biotherapeutics during the 4th quarter worth approximately $1,259,000. BVF Inc. IL purchased a new stake in SAB Biotherapeutics in the 4th quarter valued at approximately $6,310,000. Finally, RTW Investments LP acquired a new stake in SAB Biotherapeutics during the 4th quarter valued at $6,310,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

Wall Street Analyst Weigh In

SABS has been the subject of several research reports. Oppenheimer reiterated an “outperform” rating and issued a $12.00 target price on shares of SAB Biotherapeutics in a report on Thursday, September 12th. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, August 12th. Chardan Capital reissued a “buy” rating and set a $25.00 target price on shares of SAB Biotherapeutics in a research note on Monday, September 9th. Finally, Brookline Capital Management started coverage on SAB Biotherapeutics in a research report on Friday, June 7th. They issued a “buy” rating and a $8.00 target price for the company. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $12.75.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.